Ignite Creation Date:
2024-05-05 @ 11:11 PM
Last Modification Date:
2024-10-26 @ 10:29 AM
Study NCT ID:
NCT01270542
Status:
COMPLETED
Last Update Posted:
2017-08-17
First Post:
2010-12-01
Brief Title:
Avastin for PDR Proliferative Diabetic Retinopathy
Sponsor:
University of Southern California
Organization:
University of Southern California
Study Overview
Official Title:
Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PDR
Brief Summary:
The purpose of this study is to determine the effect of anti-VEGF drug Avastin adminstration in eyes prior to surgical treatment for Traction retinal detachment TRD in patients with Proliferative Diabetic Retinopathy PDR
Detailed Description:
Traction retinal detachment TRD due to proliferative diabetic retinopathy is a blinding disease caused by contraction of fibrovascular proliferation treatment of which is limited to surgery Fibrosis and neovascularization are both associated with high levels of connective tissue growth factor CTGF and vascular endothelial growth factor VEGF in the eye Small nonrandomized studies have suggested that pre-operative adjunctive anti-VEGF administration may reduce intra- and post-operative complications and provide visual benefit in patients with this condition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None